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BACKGROUND & AIMS: Increasing visceral obesity has been convincingly shown to be 
related to risk of esophageal adenocarcinoma and its precursor, Barrett’s esophagus. 
However, the independent role of gluteofemoral obesity on the risk of Barrett’s esophagus 
has not been studied.  
METHODS: Data were from seven case-control studies participating in the international 
Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). We compared data from 
cases of Barrett’s esophagus (n=1,454) separately with two control groups: 1,850 population-
based controls and 1,949 gastroesophageal reflux disease (GERD) controls. Study-specific 
odds ratios (OR) and 95% confidence intervals (95% CI), estimated using individual 
participant data and multivariable logistic regression, were combined using random effects 
meta-analysis. 
RESULTS: We found a statistically significant inverse relationship between hip 
circumference and Barrett’s esophagus (OR=0.89; 95% CI: 0.81-0.99) compared with 
population-based controls in a multivariable model that included waist circumference. This 
association was not observed in models that did not include waist circumference. Similar 
results were observed in comparisons with GERD controls and in stratified analyses based on 
history of GERD symptoms. The inversed association with hip circumference was only seen 
among males (OR=0.85; 95% CI: 0.74-0.98 for males; OR=1.00; 95% CI: 0.80-1.25 for 
females; Pinteraction = .002). Among men with any category of waist circumference, larger hip 
circumference was associated with reduced risk of Barrett’s esophagus. Conversely, 
increasing waist circumference was associated with increased risk of Barrett’s esophagus in 
the mutually adjusted model.   
CONCLUSIONS: These findings confirm that while visceral adiposity increases risk of 
Barrett’s esophagus, gluteofemoral adiposity decreases risk, particularly among men. 
Keywords: Obesity; Esophageal Cancer; Epidemiology; Risk Factors. 
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Abdominal obesity is associated with an increased risk of esophageal adenocarcinoma 
and its precursor lesion Barrett's esophagus.1, 2 These associations remain after controlling for 
the confounding effects of gastroesophageal reflux disease (GERD) symptoms, suggesting 
that non-GERD factors are important.3 Abdominal obesity may cause a number of systemic 
effects including insulin resistance, alteration in adipokines and cytokines and systemic 
chronic inflammation.4 These systemic effects have been associated with non-esophageal 
cancers and a recent meta-analysis has found they may be important in Barrett's esophagus.5 
Abdominal obesity is also strongly associated with an increased risk of diabetes 
mellitus and cardiovascular disease.6 These risks are modified by subcutaneous fat stores in 
the hip and thigh region with gluteofemoral obesity having a protective effect.7, 8 One 
postulated mechanism for this protective effect is that gluteofemoral obesity acts as a 
metabolic "sink" reducing the levels of circulating free fatty acids, insulin and adipocytokines 
that lead to metabolic and cardiovascular disease.9 
 There are few studies examining the effects of gluteofemoral obesity on the risks of 
esophageal adenocarcinoma and Barrett’s esophagus. A large cohort study involving 391,456 
participants (of whom 124 developed esophageal adenocarcinoma during follow-up) found 
that after mutual adjustment, the risk of esophageal adenocarcinoma was strongly positively 
associated with abdominal obesity but inversely associated with gluteofemoral obesity, 
providing evidence of a protective effect of gluteofemoral obesity.10 In a case-control study 
of Barrett’s esophagus conducted among male colorectal cancer screenees, there was a 
suggestion of a similar inverse association with gluteofemoral obesity, although the precision 
of the estimates were limited by study size and sex-specific effects were unable to be 
analyzed as all participants were men.11 
 Investigating the effects of fat distribution patterns on the risk of Barrett’s esophagus 
is important in furthering our understanding of the role of obesity in Barrett’s esophagus. If 
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there is evidence that gluteofemoral obesity has a protective effect on the risks associated 
with abdominal obesity, this strongly supports the hypothesis that potentially modifiable non-
GERD metabolic factors related to abdominal obesity are important in the pathogenesis of the 
disease. In addition there are sex difference in fat distribution that may be an important factor 
in the strong sex differences seen in esophageal adenocarcinoma and Barrett’s esophagus, 
both of which are more common in men than women.12, 13  
 The Barrett’s Esophagus and Esophageal Adenocarcinoma Consortium (BEACON, 
http://beacon.tlvnet.net/) is a large international consortium that has pooled and harmonized 
detailed participant data including anthropometric measurements from seven Barrett’s 
esophagus case-control studies. Using this unique resource, the aim of this study was to 
determine the risks of Barrett’s esophagus associated with gluteofemoral and abdominal 
obesity and assess the effects of each exposure after mutual adjustment. Further, we sought to 
determine if there were sex differences in these associations and whether the associations 
with gluteofemoral and abdominal obesity were confounded or modified by other known risk 
factors for Barrett’s esophagus.
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Methods 
Study population 
We analyzed individual participant data from independent case-control studies 
participating in BEACON. BEACON was formed in 2005 in collaboration with the US 
National Cancer Institute and now includes seven case-control studies on 1759 Barrett’s 
esophagus cases, 2461 population-based controls and 2516 GERD controls: the Study of 
Digestive Health (Brisbane, Australia)14; the Factors Influencing the 
Barrett’s/Adenocarcinoma Relationship (FINBAR) study (Ireland)15; the Epidemiology and 
Incidence of Barrett’s Esophagus study (Kaiser Permanente, Northern California; KPNC)16; 
the Study of Reflux Disease (western Washington State)17; the Epidemiologic Case-Control 
Study of Barrett’s Esophagus (Chapel Hill, North Carolina; UNC-Chapel Hill); the Houston 
Barrett’s Esophagus study18; and The Newly Diagnosed Barrett’s Esophagus Study (Ann 
Arbor, Michigan)11. Details of the case-control studies and data pooling methods for 
BEACON have been described in detail elsewhere.19, 20 Cases included persons with 
endoscopic evidence of columnar mucosa in the tubular esophagus, accompanied by the 
presence of specialized intestinal metaplasia in an esophageal biopsy. The studies included a 
mix of cases with prevalent and newly diagnosed Barrett’s esophagus.19 The cases are 
compared with population-based controls, that represent the source population from which 
the cases arose, and GERD controls, the population undergoing endoscopy from which BE 
cases are diagnosed. The original studies and the current data pooling were approved by the 
institutional review board or research ethics committee of each sponsoring institution. 
Written informed consents were obtained from all study subjects. 
For the current analysis, we excluded persons with missing data for waist and hip 
circumferences (425 population-based controls, 408 GERD controls and 206 Barrett’s 
esophagus cases). We additionally restricted our analyses to white non-Hispanic study 
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participants (1850 population-based controls, 1949 GERD controls, 1454 Barrett’s esophagus 
cases) due to low numbers of cases from non-white ethnic groups. Six studies provided a 
population-based control group and five studies provided a GERD control group (Table 1). 
 
Study variables 
At interview, the following anthropometric measures were collected in-person using 
study-specific protocols: height, weight, waist circumference, and hip circumference. In the 
Kaiser Permanente study, measurements of mid-thigh circumference were taken instead of 
hip circumference.16 We calculated body mass index (BMI) as weight in kilograms divided 
by height in meters squared (kg/m2). In addition to the anthropometric data, individual-level 
harmonized clinical, demographic, and questionnaire data for each study participant were 
merged into a single de-identified dataset and included information on study, case-control 
status, age at diagnosis for cases and age at study enrolment for controls, sex, ethnicity, 
highest level of education, history of GERD symptoms and cigarette smoking. The data were 
checked for consistency and completeness and any apparent inconsistencies were followed-
up with individual study investigators. 
 
Statistical analysis 
The primary aim of the analysis was to examine the associations of hip circumference 
and waist circumference (in tertiles and as a continuous measure) and the effect of each 
exposure after mutual adjustment with the risk of Barrett’s esophagus. Because distributions 
of anthropometric measures varied across studies and sexes, we derived study- and sex-
specific tertiles for hip and waist circumferences. We used a two-step analytic approach.21 In 
the first stage, study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were 
estimated using unconditional logistic regression models. In the second stage, the study-
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specific ORs were combined using random-effects meta-analytic models to generate 
summary ORs. We excluded studies from the second-step if the logistic regression model 
failed because of instability. We used the inconsistency index, I2, to assess heterogeneity 
between studies.22 Larger I2 values reflect increasing heterogeneity, beyond what is 
attributable to chance. I2 values of 25%, 50% and 75% were used as evidence of low, 
moderate, or high levels of heterogeneity, respectively. 
Exposure variables were assessed in relation to risk of Barrett’s esophagus using 
population-based controls and GERD controls as comparison groups. Our approach was, first, 
to examine the unadjusted associations of hip circumference and waist circumference with 
risk of BE. We then adjusted for age (<50, 50-<60, 60-<70, ≥70 years), sex, education 
(school only, technical college/diploma, university/college), and smoking status (never, ever). 
Finally, we further mutually adjusted for hip and waist circumference to examine their 
independent effects on risk of Barrett’s esophagus. Models that compared cases with 
population-based controls were also subsequently adjusted for self-reported GERD symptoms 
(never vs ever) to evaluate potential confounding effects of GERD symptoms. The lowest 
tertile for each categorical variable was used as the reference category. We evaluated 
continuous variables to test for linear trend by using OR per 5 cm increase in hip and waist 
circumference. 
Finally, using the same methodology as for the overall analyses, we conducted 
stratified analyses by sex and GERD symptoms to assess potential effect modification. We 
included interaction terms (hip circumference X sex and hip circumference X GERD) in the 
full models to assess the statistical significance of the difference in association across strata.  
All tests for statistical significance were two-sided at α=0.05 and analyses were 
conducted using Stata 13.1 (StataCorp LP, College Station, TX). 
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Results 
The numbers of cases and controls, and summary data for anthropometric 
measurements by study, are shown in Table 1. Cases were older, on average, than GERD 
controls but not population-based controls (Table 2). As expected, cases were more likely 
than controls to have smoked and report having had GERD symptoms (Table 2). 
 Table 3 shows the estimates of association between waist and hip circumferences and 
Barrett’s esophagus compared with both population-based controls and GERD controls. After 
adjusting for age, sex, education, and smoking status, waist circumference was positively 
associated with risk of Barrett’s esophagus (population-based controls: summary OR per 5cm 
increase = 1.05; 95% CI: 0.99-1.12; GERD controls: summary OR per 5cm increase = 1.06; 
95% CI: 1.03-1.09). After further adjustment for hip circumference, the magnitude of the 
association between waist circumference and Barrett’s esophagus was strengthened 
(population-based controls: summary OR per 5cm increase = 1.14; 95% CI: 1.04-1.24; 
GERD controls: summary OR per 5cm increase = 1.10; 95% CI: 1.02-1.18).  
 In contrast, there was no association between hip circumference and risk of Barrett’s 
esophagus in the unadjusted model or in the model adjusted for only age, sex, education, and 
smoking status (Table 3). However, after further adjustment for waist circumference, we 
found an inverse association between hip circumference and risk of Barrett’s esophagus 
(population-based controls: summary OR per 5cm increase = 0.89; 95% CI: 0.81-0.99; 
GERD controls: summary OR per 5cm increase = 0.95; 95% CI: 0.85-1.07) (Figure 1). The 
associations with waist and hip circumference were essentially unchanged after additional 
adjustment for GERD symptoms in the models comparing cases with population-based 
controls (summary OR per 5cm increase in waist = 1.11; 95% CI: 1.01-1.23; summary OR 
per 5cm increase in hip = 0.88; 95% CI: 0.80-0.97) (Supplementary Table 1). 
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 When stratified by sex (Table 4), waist circumference was associated with increased 
risk of Barrett’s esophagus in both men and women. We found no evidence for statistical 
interaction between waist circumference and sex in relation to risk of Barrett’s esophagus 
(population-based controls: Pinteraction = .11). However, hip circumference was inversely 
associated with Barrett’s esophagus in men (population-based controls: summary OR per 
5cm increase = 0.85; 95% CI: 0.74-0.98) but was not associated with Barrett’s esophagus in 
women (population-based controls: summary OR per 5cm increase = 1.00; 95% CI: 0.80-
1.25; Pinteraction = .002). Similar evidence of effect modification by sex were seen when 
GERD controls were the comparison group; although the interaction term was not statistically 
significant (GERD controls: Pinteraction = .40). We additionally performed analyses separately 
in individuals with and without GERD symptoms and found no evidence for effect 
modification by GERD symptoms (Table 5).  
 Supplementary Table 2 displays the estimated effects of combinations of categories of 
waist circumference and hip circumference. Among men with any category of waist 
circumference, larger hip circumference is associated with decreasing risk of Barrett’s 
esophagus. Men at the highest risk of Barrett’s esophagus simultaneously have waist 
circumference in the highest tertile and hip circumference in the lowest tertile. Men at the 
lowest risk of Barrett’s esophagus have waist circumference in the lowest tertile and hip 
circumference in the highest tertile. The pattern was different for women with hip 
circumference not reducing the risk of Barrett’s esophagus; however, these analyses were 
limited by smaller numbers of women in all categories. 
 There was evidence of low to moderate heterogeneity for the association between hip 
circumference (continuous) and Barrett’s esophagus. This heterogeneity was mainly driven 
by a stronger inverse association from The Newly Diagnosed Barrett’s Esophagus Study. 
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When this study was excluded, I2 reduced from 46% to 12%. Importantly the effect estimate 
was only minimally attenuated and hip circumference remained inversely associated with 
Barrett’s esophagus (summary OR per 5cm increase in hip = 0.92; 95% CI: 0.85-1.00). 
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Discussion 
We conducted pooled analyses of seven case-control studies, examining the independent 
effects of abdominal obesity and gluteofemoral obesity on the risk of Barrett’s esophagus. As 
has been shown previously, we confirmed that abdominal obesity is associated with Barrett’s 
esophagus. But in addition, we found that gluteofemoral obesity was inversely associated 
with Barrett’s esophagus. This association was strongest when we compared cases with 
population-based controls, and persisted even after adjusting for GERD symptoms. Finally, 
we found evidence of modification of the effect of gluteofemoral obesity by sex; the effect 
was only present among men, and not among women. 
 In a prior cohort study, Steffen et al. found that gluteofemoral obesity was inversely 
associated with risk of esophageal adenocarcinoma, adjusting for abdominal obesity.10 
However, that study was not able to adjust for potential confounding by GERD. In a prior 
case-control study, Rubenstein et al. found that gluteofemoral obesity was inversely 
associated with a combined outcome of Barrett’s esophagus or erosive esophagitis, adjusting 
for abdominal obesity, but the study was too small to accurately estimate the effect on 
Barrett’s esophagus alone, and did not include any women.11 Gluteofemoral obesity has 
previously been shown to be protective against diabetes mellitus and cardiovascular disease.7, 
8 Adipose tissue in the gluteofemoral compartment behaves differently metabolically than 
adipose tissue in the abdominal compartment.7, 9, 23 It has been hypothesized that 
gluteofemoral adipose tissue may serve as a “metabolic sink” where excess calories can be 
safely stored without detrimental metabolic effects. Our finding of an inverse association of 
gluteofemoral obesity with Barrett’s esophagus strongly suggests that abdominal obesity is a 
risk factor not only due to a mechanical effect promoting GERD, but also a metabolic effect. 
Multiple studies have demonstrated an association between levels of multiple different 
circulating adipokines and Barrett’s esophagus or esophageal adenocarcinoma.5, 24-27 It seems 
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unlikely that a single factor is responsible for all of the risk attributable to obesity; rather it 
would seem that abdominal obesity (if not counteracted by gluteofemoral obesity) results in a 
milieu of circulating metabolic factors that promote Barrett’s esophagus and esophageal 
adenocarcinoma. 
 Importantly, we found evidence for modification of the effect of gluteofemoral 
obesity by sex. There was no evidence of a protective effect among women. For unclear 
reasons, men are at much greater risk than women for Barrett’s esophagus,28 and especially 
for esophageal adenocarcinoma.29, 30 Women and men differ in their distribution of adipose 
tissue, with men having 52% greater intra-abdominal fat mass and 30% less subcutaneous fat, 
including gluteofemoral fat, than women.31 In addition, estrogen regulates the secretion of 
adipokines from adipose tissue.32 Taken together, these findings suggest that the differential 
compartments for deposition of adipose tissue and metabolic effects may explain much of the 
risk of male sex for Barrett’s esophagus.  
 Our study had some limitations. First, we were only able to study the outcome of 
Barrett’s esophagus, and not esophageal adenocarcinoma. In addition, the studies included a 
mix of patients with newly diagnosed and prevalent diagnoses of Barrett’s esophagus, which 
could have biased the results unpredictably. Finally, there was moderate heterogeneity in 
some effect estimates. However, there are also a number of strengths to the study. Notably, 
we were able to combine data from seven independent studies from different geographic 
regions. The component studies used a uniform diagnosis of Barrett’s esophagus, and all 
measured anthropometrics rather than using self-report. We were able to compare the effects 
to both population controls and GERD controls, adjust for a number of important potential 
confounders, and examine for effect modification by sex. 
 In summary, we found a protective effect of gluteofemoral obesity on the risk of 
Barrett’s esophagus in the setting of abdominal obesity among men. The association is 
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independent of GERD, and not present in women. These findings support a metabolic 
explanation for the effect of obesity on Barrett’s esophagus and for the risk of male sex on 
Barrett’s esophagus.  Further studies are required to determine whether the distribution of 
obesity and metabolic effects promote the progression from Barrett’s esophagus to 
esophageal adenocarcinoma, and whether modifying these factors can prevent the cancer. 
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Figure 1 Forest plot of the association between increasing tertiles of hip circumference and 
risk of Barrett’s esophagus compared with (A) population-based controls and (B) GERD 
controls. Models included terms for age (<50, 50-<60, 60-<70, 70+), education (except 
UNC), smoking (ever, never), and were simultaneously adjusted for waist circumference and 
hip circumference.
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